Results 71 to 80 of about 824,117 (206)

T‐Cell Remodeling in Renal Fibrosis: From Acute Injury to Chronic Kidney Disease

Advanced Science, EarlyView.
This Review presents renal fibrosis as a sequence of overlapping T‐cell programs, from chemokine‐guided recruitment and metabolic activation to maladaptive polarization, tertiary lymphoid structure formation, tissue residency, exhaustion, and senescence.
Qianhui Li, Junting Guan, Yifan Song, Hongxia Yang, Guangtao Li, Xiaodong Zhao, Jiaxin Liu, Bin Liu, Yang Tan, Honglan Zhou, Yang‐He Zhang, Yishu Wang   +11 more
wiley   +1 more source

Maraviroc enhances Bortezomib sensitivity in multiple myeloma by inhibiting M2 macrophage polarization via PI3K/AKT/RhoA signaling pathway in macrophages

Cell Division
Background Multiple myeloma (MM) is a malignancy where drug resistance often leads to relapse or refractory disease. Chemokine receptor 5 (CCR5) has emerged as a novel therapeutic target.
Huiye Yang, Yuchan He, Fujun Qu, Jie Zhu, Liyuan Deng, Fang Jiang, Xianyi Wu, Yixuan Chen, Ali Kashif, Xiaotao Wang   +9 more
doaj   +1 more source

Engineering Biology Beyond Single Genes: Advances and Challenges in Multiplex Genome Editing

Animal Research and One Health, EarlyView.
Multiplex genome editing is transforming genome engineering from single‐gene perturbation to network‐level control, yet its broader application remains limited by challenges in gRNA array engineering, delivery technologies, and safety management. Emerging AI‐driven approaches are accelerating guide RNA design and CRISPR effector optimization for ...
Linli Wang, Yongbin Liu, Hongbing Han
wiley   +1 more source

Development and Bioanalytical Validation of a Liquid Chromatographic-Tandem Mass Spectrometric (LC-MS/MS) Method for the Quantification of the CCR5 Antagonist Maraviroc in Human Plasma

Clinica chimica acta; international journal of clinical chemistry, 2014
Background Maraviroc is a CCR5 antagonist that has been utilized as a viral entry inhibitor in the management of HIV-1. Current clinical trials are pursuing maraviroc drug efficacy in both oral and topical formulations.
J. Emory, Lauren A Seserko, M. Marzinke
semanticscholar   +1 more source

Autoreactivity Versus Autoimmunity: Characteristics of Autoantigen‐Specific CD4 T Cells in Rheumatoid Arthritis and Health

Arthritis &Rheumatology, EarlyView.
Objective CD4 T cells specific for citrullinated (cit) peptides are key players in rheumatoid arthritis (RA) immunopathogenesis. Characterizing these cells and identifying features of healthy and RA‐associated autoreactivity will provide valuable insight into disease mechanisms and form the basis of immune state biomarkers to facilitate the next ...
James A. Stanway, Daniel Peters, Helen Waller, Jeremy Lakey, Henrique De Paula Lemos, Kristian Williams, Abbie Degnan, Julie Diboll, Abdul Mannan Baru, David Tough, Arthur G. Pratt, Catharien M.U. Hilkens, Amy E. Anderson, John D. Isaacs   +13 more
wiley   +1 more source

Cellular tropism of HIV-1 mediated and contrained by coreceptor dependencies [PDF]

, 2005
The ability of cells to migrate to specific sites is critical for the proper functioning of both innate and adaptive immune responses in primates. This selective responsiveness is largely orchestrated by small proteins known as chemokines, which direct ...
Nolan, D., Gaudieri, S., Lucas, A.D., Rauch, A., Mallal, S.   +4 more
core  

Comparative Docking Study of Anibamine as the First Natural Product CCR5 Antagonist in CCR5 Homology Models

, 2016
Anibamine, a novel pyridine quaternary alkaloid recently isolated from Aniba sp., has been found to effectively bind to the chemokine receptor CCR5 with an IC50 at 1 μM in competition with 125I-gp120, an HIV viral envelope protein binding to CCR5 with ...
Glen E. Kellogg (204170), Guo Li (174860), Yan Zhang (8098), Kendra M. Haney (2162569)   +3 more
core   +1 more source

Characterization of a CXCR4 antagonist TIQ-15 with dual tropic HIV entry inhibition properties.

PLoS Pathogens
The chemokine co-receptors CXCR4 and CCR5 mediate HIV entry and signal transduction necessary for viral infection. However, to date only the CCR5 antagonist maraviroc is approved for treating HIV-1 infection.
Zheng Zhou, Jia Guo, Brian Hetrick, Sameer Tiwari, Amrita Haikerwal, Yang Han, Vincent C Bond, Ming B Huang, Marie K Mankowski, Beth A Snyder, Priscilla A Hogan, Savita K Sharma, Dennis C Liotta, Terry-Elinor Reid, Lawrence J Wilson, Yuntao Wu   +15 more
doaj   +1 more source

Persistent Interleukin‐18 Fuels Expansion of CD38+HLA‐DR+CD8+ T Cells in Still Disease and Macrophage Activation Syndrome

Arthritis &Rheumatology, EarlyView.
Objective Still disease (SD) is an autoinflammatory disorder characterized by remarkably high interleukin‐18 (IL‐18) levels. Increasing evidence suggests that adaptive immunity also contributes to its pathogenesis, particularly in refractory courses. Macrophage activation syndrome (MAS), one of SD's most severe complications, is associated with further
Greta Rogani, Remco G. A. Erkens, Alejandra Bodelón, Tim R. Mocking, Marein T. M. Putmans, Freya M. C. H. Huijsmans, Lyanne J. P. M. Sijbers, Aafke M. De Ligt, Maurice J. H. Van Haaren, Rianne C. Scholman, Noël M. M. Dautzenberg, Joyce I. Meesters‐Ensing, Martina Rossano, Laura Porretti, Stefan Nierkens, Francesca S. Minoia, Sebastiaan J. Vastert, Jorg van Loosdregt   +17 more
wiley   +1 more source

Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND)

Journal of Neurovirology, 2014
HIV-associated neurocognitive disorders (HAND) continues to be prevalent (30–50 %) despite plasma HIV-RNA suppression with combination antiretroviral therapy (cART). There is no proven therapy for individuals on suppressive cART with HAND.
L. Ndhlovu, Tracie M Umaki, G. Chew, D. Chow, M. Agsalda, K. Kallianpur, R. Paul, Guang-Xiang Zhang, E. Ho, N. Hanks, B. Nakamoto, B. Shiramizu, C. Shikuma   +12 more
semanticscholar   +1 more source